Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSeattle Children'S Hospital

China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A